Autor(es): Coelho, André ; Alvites, Rui Damásio ; Branquinho, Mariana Vieira ; Guerreiro, Susana G. ; Maurício, Ana Colette
Data: 2020
Identificador Persistente: http://hdl.handle.net/10400.22/16649
Origem: Repositório Científico do Instituto Politécnico do Porto
Assunto(s): Cell-based therapies; Secretome; Mesenchymal stem cells; Coronavirus; SARS-CoV-2
In 2019, an outbreak of an unknown coronavirus – SARS-CoV-2 – responsible for COVID-19 disease, was first reported in China, and evolved into a pandemic of huge dimensions and raised serious concerns for global health. The number of critical cases continues to increase dramatically, while vaccines and specific treatments are not yet available. There are several strategies currently being studied for the treatment of adverse symptoms of COVID-19, that encompass Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS), extensive pulmonary inflammation, cytokine storm, and pulmonary edema, due to virus-induced pneumonia.
